- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
FDA Recruits Bioethicist Charo to Its Top Ranks
6 August 2009 5:23 pm
Bioethics expert R. Alta Charo is joining the U.S. Food and Drug Administration as a senior adviser to FDA Commissioner Margaret Hamburg. In an interview Wednesday, Hamburg said that Charo will be involved in many cutting-edge fields. "I expect that we will quickly make use of her as we think about strategies on how to address the review of products in the arena of personalized medicine, in-vitro diagnostics, stem-cell therapies, where she's already done important work," Hamburg said.
Charo, on the law faculty of the University of Wisconsin, Madison, has written extensively on the ethics of embryonic stem cell research, served on President Barack Obama's FDA transition team, and was a member of President Bill Clinton's bioethics advisory council. Charo's influence at FDA will be "broader than bioethics," said Hamburg."She also is an expert on food and drug law," areas in which her advice will be welcome. The FDA director said that she and her staff are looking forward to working with the National Institutes of Health on establishing a regulatory framework for assessing new medical diagnostics and treatments. "I think that, working together, we will be able to put in place a strategic framework to make sure that the scientific opportunities can translate into available products, with appropriate regulatory review." Charo has said that she hopes to focus on developing a comprehensive approach to regulating genetic tests.